Plain-English translation of NCT05355051 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether combining two medications— and azacitidine—can help patients whose Hodgkin's lymphoma has returned or stopped responding to earlier treatments. Researchers want to see how well this medication combination works and whether it's safe for patients, including younger people. The study will enroll about 24 people at M.D. Anderson Cancer Center.
Hodgkin's lymphoma can sometimes come back after initial treatment, and some patients don't respond well to standard chemotherapy. Doctors are hoping that this medication combination might offer a new option for patients in these difficult situations.
You likely qualify if…
You likely don't qualify if…
You would receive as an infusion through a vein every 3 weeks, which takes about 30 minutes. You would also receive azacitidine as an infusion on days 1–7 of each 28-day cycle, which takes about 60–90 minutes. The study lasts as long as the treatment is helping and you want to continue. Your doctors will regularly check how well the medication is working and monitor you for any side effects.
AI-generated summary from trial data · Jul 3, 2026 · Not medical advice
United States
Phase
Testing effectiveness
Sponsor
M.D. Anderson Cancer Center
Enrollment target
~24 participants
Started
October 2022
Primary completion
December 2026
Age range
1 Year and older
Last updated on clinicaltrials.gov in May 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
David McCall, MD
M.D. Anderson Cancer Center
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.